Smad4 functions as a transcription factor in TGF-b signalling. We have investigated the role of Smad4 in the TGF-b 1 cell responses of transformed PDV keratinocytes, which contain a Ras oncogene, and of nontumorigenic MCA3D keratinocytes, by transfecting both cell lines with a dominant-negative Smad4 construct. Smad4 mediates TGF-b 1 -induced up-regulation of p21 Cip1 and growth arrest in MCA3D cells. However, in PDV keratinocytes, Smad4 is only partially involved in TGFb 1 -induced growth inhibition, and does not mediate enhancement of p21
Introduction
Transforming growth factor-b (TGF-b) regulates cell proliferation, dierentiation, motility, adhesion, and death in most tissues, including epithelia (MassagueÂ , 1990; Lahio and Keski-Oja, 1992) . During the last years the idea of a dual function of TGF-b in epithelial carcinogenesis has gained considerable support. TGF-b acts as a suppressor of tumour formation by virtue of its role in inhibiting proliferation of epithelial cells (Alexandrow and Moses, 1995; MassagueÂ , 1998) , but it also stimulates malignant progression at later stages of tumorigenesis by inducing an epithelial-mesenchymal transition associated with the development of a highly aggressive undierentiated type of tumour (CaulõÂ n et al., 1995; Cui et al., 1996; Oft et al., 1996 Oft et al., , 1998 Frontelo et al., 1998; Portella et al., 1998) .
Studies on the mouse skin carcinogenesis model and on mammary epithelial cells suggest a synergistic cooperation between oncogenic Ras and TGF-b 1 to stimulate malignant progression (Oft et al., 1996; Akhurst and Balmain, 1999) . The eects of the growth factor on carcinoma cell invasiveness and metastasis appear to be direct and require signalling through the type II receptor (Oft et al., 1998; Portella et al., 1998) .
TGF-b signals through formation of heteromeric complexes between type I and type II serine/threonine kinase receptors. After activation, the signal transducing type I receptor binds and phosphorylates Smad2/ Smad3 proteins that associate with Smad4 in the cytoplasm, and these complexes, then, translocate into the nucleus in which they activate transcription of speci®c genes (see MassagueÂ , 1998; Zhang and Derynck, 1999 ; for reviews). TGF-b signalling components, such as type II receptors and Smad proteins, have been shown to be inactivated by mutation or deletion in human cancers (MassagueÂ , 1998) . Particularly, Smad4 (DPC4) was originally identi®ed as a tumour suppressor gene frequently inactivated in pancreatic and colon carcinomas. Reconstitution of Smad4 in colon carcinoma defective cells leads to suppression of tumorigenicity (Schwarte-Waldho et al., 1999) Several reports point to a rapid and direct activation of the Ras-mitogen-activated protein (MAP) kinase signalling pathway associated with growth inhibition by TGF-b in epithelial cells (Hartsough et al., 1996; reviewed in Hartsough and Mulder, 1997) . The growth inhibitory response to TGF-b appears to be mediated by induction of cyclin-dependent kinase (cdk) inhibitors, such as p21
Cip1 and p15 INK4B (Datto et al., 1995; Hannon and Beach, 1994; ReynisdoÂ ttir et al., 1995) . The signalling pathways involved in these TGF-binduced gene responses remain an open question (see MassagueÂ , 1998) . Thus, p21 Cip1 appears to be a downstream target gene regulated by Smad4 in carcinoma cells (Grau et al., 1997; Hunt et al., 1998) , while it has been reported that Ras and the MAP kinase pathway are required for up-regulation of p21
Cip1 by TGF-b in intestinal epithelial cells and human keratinocytes, respectively (Yue et al., 1998; Hu et al., 1999) . The same appears to occur for TGF-bmediated induction of other genes, such as the 3TP-lux reporter construct, which contains a known TGF-binducible plasminogen activator inhibitor-1 (PAI-1) promoter (Grau et al., 1997; Mucsi et al., 1996; de Winter et al., 1997) . This scenario has been complicated as several reports demonstrate a cross-talk between the Smad and Ras-MAP kinase signalling pathways (reviewed in Zhang and Derynck, 1999) . Recently, Kretzschmar et al. (1999) found that oncogenic Ras, acting via MAP kinases, inhibits TGF-b-induced nuclear accumulation of Smad2 and Smad3. However, another report has shown that constitutively active MEK, or inhibitors for MEK, have no eect on Smad activity in human keratinocytes (Hu et al., 1999) .
In this work, we have analysed the role of Smad4 in the TGF-b 1 responses of immortalized (MCA3D) and transformed (PDV) mouse epidermal keratinocytes by transfecting both cell lines with a C-terminal truncated, dominant-negative, Smad4 construct (Lagna et al., 1996) . MCA3D cells are non-tumorigenic and exhibit normal Ras and p53 genes, while PDV are chemically transformed keratinocytes and produce low metastatic well dierentiated squamous cell carcinomas upon injection in mice (CaulõÂ n et al., 1995; Frontelo et al., 1998) . PDV cells contain a mutated H-Ras gene and express relatively low levels of activated Ras proteins (Quintanilla et al., 1991) . They also have inactivated p53 loci (Burns et al., 1991) . Both cell lines are growthinhibited by TGF-b 1 , but they respond dierentially to chronic treatment with the growth factor. While MCA3D cells are induced to terminal dierentiation and cell death in response to TGF-b 1 , the growth factor stimulates cell motility and invasiveness in PDV cells, which undergo a reversible epithelial-mesenchymal conversion linked to progression toward a metastatic poorly dierentiated tumour phenotype (CaulõÂ n et al., 1995; Frontelo et al., 1998) . The invasive response of PDV and other carcinoma cells to TGF-b 1 is associated with enhanced expression/secretion of urokinase (uPA) and of its inhibitor PAI-1 (Farina et al., 1998; SantibaÂ nÄ ez et al., 1999) . uPA is a serine proteinase that converts the inactive plasminogen into the broad-spectrum active proteinase plasmin, which in turn degrades many proteins of the extracellular matrix and activates other matrix metalloproteinases (Andreasen et al., 1997) .
We show that inhibiting Smad4 in Ras-transformed keratinocytes leads to hyperactivation of the Ras/Erk signalling pathway, increased secretion of uPA, and progression to a poorly dierentiated tumour phenotype. On the other hand, a switch between the Smad and Erk signalling pathways, depending on the presence of oncogenic Ras, appears to occur in keratinocytes to mediate induction of p21
Cipl by TGFb 1 .
Results

Smad4 mediates growth inhibition in both MCA3D and PDV keratinocytes
MCA3D and PDV cell lines were transfected either with a full-length Smad4 cDNA or with a C-terminal truncated dominant-negative Smad4 (1 ± 514) construct, together with the pcDNA3 neomycine resistant vector. Previously, the presence of Smad4 transcripts in both cell lines was demonstrated by RT ± PCR (data not shown). After transfection with the normal full-length cDNA, no viable clones were obtained from MCA3D cells; while several clones could be selected up to the third passage, in which they died, in the case of PDV cells. These results suggest that overexpression of Smad4 induces cell death in keratinocytes, as reported for other epithelial cells , although this hypothesis was not further investigated. Stable clones transfected with the dominant-negative Smad4 (1 ± 514) construct were isolated from both MCA3D and PDV cell lines (designated as 3DdnS and PdnS, respectively). Clones transfected with the pcDNA3 vector alone were also obtained (designated as 3DC and PC) to be used as controls.
The activity of Smad signalling in the transfectants was analysed by measuring TGF-b 1 -induced nuclear accumulation of Smad2/Smad3 in immuno¯uorescence experiments using a speci®c anti-Smad2,3 antibody ( Figure 1 ). In exponentially growing MCA3D and PDV cells, untreated with TGF-b 1 , anti-Smad2,3 staining was predominantly cytoplasmic concentrated at the perinuclear region, although about 18% of the cells showed Smad2/Smad3 accumulated in the nucleus (Figure 1a,b) . This percentage of unstimulated cells with Smad2,3 localized into the nucleus was probably as consequence of TGF-b factors present in the serum or secreted by their own cells. In any case, on addition of TGF-b 1 , about 90% of MCA3D cells showed antiSmad2,3 staining concentrated into the nucleus. This response was rapid, with a maximum at 20 min, and lasted for about 1 h (Figure 1b) . PDV cells responded partially to TGF-b 1 -induced nuclear translocation of Smad2,3. Anti-Smad2,3 nuclear staining was limited to about 40% of the cells at 30 min of treatment ( Figure  1a,b) , indicating a constitutive inhibition of Smad signalling in these transformed keratinocytes, likely because of the presence of a Ras oncogene (Kretzschmar et al., 1999) . 3DdnS and PdnS transfectants did not respond to TGF-b 1 for nuclear accumulation of Smad2,3 (see in Figure 1c the results obtained with 3DdnS18, PdnS7 and PdnS8; other clones, such as 3DdnS16, 3DdnS17 and PdnS5, behaved similarly), while nuclear translocation of Smad proteins was stimulated in control clones as in the corresponding parental cell lines (not shown). These results clearly indicated that the Smad transduction pathway was blocked in the dominant-negative Smad4 transfectants.
Although MCA3D cells are most sensitive than PDV for TGF-b 1 -induced growth inhibition, both cell lines are growth-inhibited by concentrations of TGF-b 1 above 1 ng/ml . As shown in Figure 2 , TGF-b 1 , at 10 ng/ml, inhibited the growth of 3DC and PC control cell clones after 48 h of treatment. All of the dominant-negative Smad4 transfectant clones showed resistance to growth inhibition, but, while it was drastically reduced in 3DdnS cells (Figure 2a) , a signi®cant inhibition of growth was still induced by TGF-b 1 in PdnS clones (Figure 2b ), suggesting that other signalling pathways, in addition to Smad, could be involved in the antiproliferative response of transformed keratinocytes to TGF-b 1 .
We also analysed the activation by TGF-b 1 of 3TP-lux, a TGF-b-inducible reporter gene containing a PAI-1 promoter. Previous results indicated that TGFb 1 induced a twofold activation of 3TP-lux in PDV cells after 24 h of treatment, while MCA3D cells were unable to respond to the growth factor for PAI-1 induction (SantibaÂ nÄ ez et al., 1999) . As shown in Figure  2c , TGF-b 1 activated 3TP-lux in the control PC2 clone (about twofold), while no signi®cant activation of the reporter gene was found in PdnS transfectants. This result indicates that Smad4 is a key element in the TGF-b signal transduction cascade in transformed keratinocytes.
Smad4 mediates up-regulation of p21
Clp1 by TGF-b 1 in MCA3D, but not in PDV cells in which the Erk signalling pathway is required It has been demonstrated that TGF-b 1 induces the expression of the cdk inhibitor p21
Cip1 in normal and transformed keratinocytes, and that induction of p21
Cip1
, together with alterations in other cell cycle regulatory molecules, seems to be partially responsible of the growth-inhibitory eects of TGF-b 1 (Malliri et al., 1996) . We studied the expression of Cip1 were observed between control PC and dominant-negative PdnS transfectants (Figure 3b, c) . Since the Erk MAP kinase signalling pathway has also been implicated in the regulation of p21
Cip1 by TGF-b in epithelial cells (Yue et al., 1998; Hu et al., 1999) , we studied the eects of PD098059, a speci®c inhibitor of MAP kinase kinase (MEK) (Simon et al., 1996) , on p21 Cip1 protein induction by TGF-b 1 . PD098059, at a concentration of 50 mM (that is shown to inhibit eciently Erk signalling activity in PDV cells, see Cip1 by the growth factor in 3DC cells (Figure 3c ). Altogether, these data indicated that Smad4 does not mediate regulation of p21
Cip1 protein levels by TGF-b 1 in transformed PDV keratinocytes, and that this response appeared to require Erk MAP kinase signalling activity.
To study whether the expression of oncogenic Ras could explain the involvement of Erk in the modulation of p21
Cip1 levels by TGF-b 1 in PDV cells, we infected 3DC and 3DdnS transfectants with retroviruses carrying an activated H-Ras gene, and analysed the levels of p21
Cip1 in the absence and presence of TGF-b 1 . Infection of the cells with the Harvey murine sarcoma virus (HMSV) produced a relatively high level of oncogenic Ras protein expression (see below), and resulted in a strong basal induction (4 ± 7-fold) of p21
Cip1 protein levels ( Figure  3d ,e). This increase was similar to that induced by TGF-b 1 in non-infected 3DC cells (Figure 3d ), and occurred in both control and dominant-negative Smad4 transfectants. p21
Cip1 protein levels in Rasinfected cells were signi®cantly reduced by treatment with PD098059 ( Figure 3e ).
TGF-b 1 induces a rapid and transient activation of Ras and Erk in MCA3D and PDV keratinocytes
Therefore, we studied whether TGF-b 1 was able to activate the Ras/Erk signalling pathway in MCA3D and PDV keratinocytes. Ras signalling activity was analysed by measuring the levels of Ras-GTP in unstimulated and TGF-b 1 -stimulated cells ( Figure 4 ). As expected, the basal level of active Ras-GTP was strikingly higher in PDV compared to MCA3D cells. TGF-b 1 induced a rapid and transient enhancement of Ras-GTP levels in both cell lines, without changing Ras protein expression. Maximal activation for both cell lines occurred at 2 min of treatment, and a decay to baseline levels at about 10 min (Figure 4a,b) .
We also studied the activity of Erk by analysing the immuno¯uorescent localization of Erk proteins using an antibody that recognizes both Erk1 and Erk2 isoforms. Activation of Erk occurs in the cytoplasm and implies phosphorylation by MEK and translocation into the nucleus (Davis, 1993; Hill and Treisman, 1995) . As shown in Figure 5a ,b, Erk proteins were found mostly in the cytoplasm of unstimulated MCA3D and PDV cells, and only a small percentage of the cell population (below 5% in MCA3D and about 12% in PDV) exhibited Erk nuclear localization. The higher percentage of Erk nuclear accumulation in PDV cells indicated a certain constitutive activation of Erk signalling in basal conditions, consistent with the presence of elevated levels of Ras-GTP in this latter cell line. On TGF-b 1 addition, Erk proteins were transiently translocated into the nucleus in about 90% of both MCA3D and PDV cells, although with a slight dierence in their kinetic pro®les: Maximal nuclear accumulation occurred at 15 ± 30 min (PDV) and 30 ± 60 min (MCA3D), and the ®nal slope of the kinetics was more pronounced in MCA3D cells (Figure 5a ).
The eect of the MEK inhibitor PD098059 on TGFb 1 -induced nuclear translocation of Erk was analysed in PDV cells. Treatment of the cells with increasing concentrations of PD098059 resulted in a dosedependent inhibition of Erk nuclear accumulation (Figure 5c ). Inhibition was none at 10 mM, partial at 25 mM, and complete at 50 mM. TGF-b 1 stimulated the levels of phosphorylated Erk proteins, as shown in the Western blot of Figure 5d , in which a speci®c monoclonal antibody that recognizes the phosphorylated forms of both Erk1 and Erk2 was used. Increased phosphorylation of Erk was more evident in Erk2, did not involve changes in Erk protein expression, and was inhibited by PD098059 at 50 mM (Figure 5d ).
Blockade of Smad4 in transformed keratinocytes leads to hyperactivation of the Ras/Erk signalling pathway associated with increased secretion of urokinase and tumour progression Thereafter, we analysed the nuclear localization of Erk proteins in the transfectants before and after a treatment of 30 min with TGF-b 1 . Untreated PdnS clones consistently showed increased basal nuclear localization of Erk proteins (about 40% of the cells) respect to PC controls (about 10%); suggesting that the level of Erk signalling is further increased in PDV dominant-negative Smad4 cells. In contrast, the percentage of cells with Erk accumulated in the nucleus was similar (2 ± 3%) in untreated 3DC and 3DdnS cells (Figure 6b ), indicating that inhibition of Smad4 in non-transformed keratinocytes had no eect on the Erk pathway. TGF-b 1 stimulated nuclear translocation of Erk at the same extent (90 ± 100%) in all clones (Figure 6a,b) . In Ras-infected 3DC and 3DdnS cells, nuclear accumulation of Erk raised maximum levels in basal conditions, masking the eect of TGF-b 1 ( Figure  6b ). As expected, low levels of phospho-Erk1,2 proteins were found in 3DC and 3DdnS cells. Phosphorylation of both isoforms increased after infection with Ras or stimulation with TGF-b 1 ( Figure  6c ). In contrast, enhanced levels of phospho-Erk2, but not of phospho-Erk1, were observed in unstimulated PdnS transfectants compared with control PC4 cells (Figure 6c ). We also analysed the activity of Ras signalling by comparing the levels of Ras-GTP in PC and PdnS transfectants. PdnS7 and PdnS8 cells showed elevated levels of Ras-GTP respect to control PC4 cells, and this enhancement was not due to increased Ras protein expression (Figure 6d ). The same result was obtained with PdnS5 (not shown). These ®ndings are consistent with the idea that inhibition of Smad4 in transformed PDV keratinocytes leads to a constitutive hyperactivation of the Ras/Erk transduction pathway mediated by phosphorylation of Erk2. Treatment of PDV cells with TGF-b 1 up-regulates uPA expression/secretion associated with stimulation of cell motility and invasiveness (SantibaÂ nÄ ez et al., 1999). We show in another report that stimulation of uPA production by TGF-b 1 in PDV cells requires the Ras/Erk signalling pathway (SantibaÂ nÄ ez et al., 2000) .
Interestingly, PdnS clones consistently secreted increased amounts of uPA compared with control clones (Figure 7a ) or the parental cell line (not shown). Treatment with TGF-b 1 for 24 h stimulated uPA production about threefold in PC cells and slightly enhanced the levels of uPA secreted by some PdnS clones (Figure 7a,b) . Both basal and TGF-b 1 -induced levels of uPA secreted by PdnS cells were inhibited by PD098059 at 50 mM, which also reduced uPA secretion in TGF-b 1 -stimulated PC cells, as exempli®ed with PdnS8 and PC4 clones in Figure 7b . Nevertheless, dominant-negative 3DdnS cells did not increase basal secretion of uPA respect to the parental cell line (Figure 7c ) or control clones (not shown). In unstimulated MCA3D cells, secreted uPA was enhanced by overexpression of oncogenic Ras after retroviral infection, and this increase was also inhibited by PD098059 (Figure 7c ). The same result was obtained in 3DdnS cells (not shown).
To analyse whether enhanced secretion of uPA in PdnS clones correlated with increased motility, we performed an in vitro wound healing assay comparing the abilities of PC and PdnS clones to repopulate a wound made 24 h before (Figure 8a,b) . PdnS clones showed higher migratory abilities than PC in unstimulated conditions. TGF-b 1 enhanced cell motility of all clones, although the eect was more pronounced in control PC cells. To demonstrate the involvement of The levels of Ras bound to GTP and Ras protein expression were determined in the cell lysates (0.7 mg of total protein) as in the legend of Figure 4 Smad4 and Ras co-operate for tumour progression M lglesias et al uPA in the motility properties of the cells, we synthesized a peptide (P41 ± 54) comprising aminoacids residues 41 ± 54 of the amino-terminal domain of mouse uPA. This fragment was shown to be a potent antagonist of the binding of uPA to its high anity cell-surface receptor (Min et al., 1996) , and to inhibit TGF-b 1 -stimulated cell motility and invasiveness of PDV cells (SantibaÂ nÄ ez et al., 1999) . As shown in Figure  8a ,b, treatment with P41 ± 54 strongly reduced basal cell motility of PdnS cells, and blocked migration stimulated by TGF-b 1 in PC and PdnS clones, while unrelated control peptides had no eect (not shown). Importantly, a clear change to a ®broblastoid cell morphology was observed in PdnS clones respect to PC or PDV keratinocytes (Figure 8c ). 3DdnS transfectants, on the other hand, exhibited morphological appearances (Figure 8c ) and low migratory abilities (not shown) similar to that of the parental cell line. To analyse the behaviour of PC and PdnS clones in vivo, cells were transplanted into nude mice by i.d. injection and their tumorigenic characteristics compared (Table  1) . No signi®cant changes in the rates of tumour growth were observed between PC and PdnS clones, although PC-induced tumours tend to appear earlier. Notwithstanding, a striking dierence was observed in the tumour phenotypes ( Figure 9 , Table 1 ). PC tumours were histologically typed as well dierentiated squamous cell carcinomas (see PC2 in Figure 9 ), and only small areas moderately/poorly dierentiated were observed in two PC4 tumours (not shown). In PdnS tumours, keratinizing areas were absent (see PdnS8 in Figure 9 ), or, when present in some tumour sections (two PdnS7 and one PdnS5), representing less than 25% of the total tumour surface. Consequently, all PdnS tumours were typed as poorly dierentiated carcinomas.
Discussion
In this study we demonstrate that TGF-b 1 activates both the Ras/MAP kinase and Smad signalling pathways in keratinocytes. Smad signalling mediates TGFb 1 -induced growth arrest and up-regulation of p21 Cip1 in non-transformed MCA3D keratinocytes, as 3DdnS dominant-negative Smad4 cell transfectants exhibited a block in these responses. In transformed PDV keratinocytes, however, other pathways besides Smad are implicated for TGF-b 1 -induced growth inhibition.
Modulation of p21
Cip1 expression by TGF-b 1 in PDV cells is independent of Smad4 and requires Erk MAP kinase signalling activity. Therefore, both the Smad and MAP kinase pathways can be involved in the regulation of p21
Cip1 expression by TGF-b 1 in keratinocytes. A key factor for the dierent responses of MCA3D and PDV cells appears to be the presence of an activated Ras gene in the latter cells (Quintanilla et al., 1991) 
. Overexpression of oncogenic Ras in MCA3D cells by retroviral infection induced a high level of p21
Cip1 protein regardless of blocking Smad4 or not. These levels were comparable to that induced by TGF-b 1 in non-infected cells, and were inhibited by PD098059. The high basal level of p21
Cip1 observed in Ras-infected MCA3D compared to PDV cells is likely due to the higher oncogenic Ras dosage expressed by 3D-Ras cells. It has been demonstrated that, in certain situations, activation of Ras induces p21
Cip1 expression and cell cycle arrest via the Erk MAP kinase transduction pathway (reviewed in Lloyd, 1998) . Constitutively active Ras requires Rho signalling for suppression of p21
Cip1 induction (Olson et al., 1998) . This mechanism could be operating in PDV cells to maintain low basal levels of p21
Cip1
. In support of this hypothesis is the observation by Adnane et al. (1998) that a dominant-negative mutant of RhoA activates p21
Cip1 expression, while constitutively active RhoA repress it, in the pancreatic carcinoma cell line Panc-1, which contain an activated K-Ras gene. The fact that TGF-b 1 is able to up-regulate p21
Cip1 levels in PDV (this study) as well as in Panc-1 cells (Grau et al., 1997) might imply that the growth factor regulates negatively Rho activity. Studies aimed to evaluate the involvement of Rho GTPases in the PDV cell responses to TGF-b 1 are currently in progress.
Nevertheless, the most striking ®nding in this study is that inactivation of Smad4 in transformed PDV keratinocytes, but not in nontumorigenic MCA3D cells, leads to increased activity of the Ras/Erk signalling pathway; as found by enhanced levels of Ras-GTP, phosphorylated Erk2, and nuclear accumulation of Erk proteins, in dominant-negative PdnS transfectants compared to PC control cells. These observations suggest a new type of interaction by , 1999) , aliquots of conditioned media used for determinations of uPA were normalized for a protein concentration of 0.5 mg/ml in (a, b), and of 2.5 mg/ml in (c) which Smad4, directly or indirectly, inhibits Ras signalling activity in transformed keratinocytes, in addition to the mechanism of repression of Smad signalling by oncogenic Ras/MAP kinases proposed by Kretzschmar et al. (1999) . However, the molecular basis for this cross-talk between Smad4 and Ras remains to be investigated.
The functional consequences of inactivating Smad4 in PDV cells are increased secretion of uPA, enhanced motility, and a change toward a ®broblastoid cell morphology associated with the development of poorly dierentiated tumours. High levels of secreted uPA are commonly associated with tumoural invasiveness and metastasis and with a poor patient prognosis (Andreasen et al., 1997). The ®nding that PD098059 reduces uPA secretion in dominant-negative PdnS transfectants to levels similar to that of unstimulated PDV keratinocytes, suggest an involvement of the MAP kinase cascade to regulate enhanced production of uPA in PdnS cells, probably through hyperactivation of Ras signalling activity. In fact, the Ras/MAP kinase pathway is required for TGF-b 1 to modulate uPA expression/secretion in PDV cells (SantibaÂ nÄ ez et al., 2000) .
Taken together, our results suggest that the presence of an activated Ras gene and loss of Smad4 function cooperates for malignant progression. This co-operation might be physiologically relevant in certain tumours where oncogenic mutations in Ras coincides with functional inactivation of Smad4, as occurs in pancreatic and colon carcinomas. Pancreatic adenocarcinomas exhibit the highest rate of activating Ras (K-Ras) mutations found in human tumours with a frequency above 90% (Almoguera et al., 1988; Rozenblum et al., 1997) , and about 50% of carcinomas have inactivated Smad4 (DPC4) (Hahn and Schmiegel, Rozenblum et al., 1997) . These frequencies are lower in colon carcinomas with approximately 50% of the tumours containing mutations in K-Ras (Bos et al., 1987; Burmer et al., 1990) and about 15% loss of Smad4 (DPC4) (MacGrogan et al., 1997; Thiagalingam et al., 1996) . It would be of clinical interest to analyse whether the combination of an oncogenic Ras mutation (an early event in carcinogenesis) and inactivated Smad4 suppressor genes (a late event) is a prognostic factor for the development of more malignant undierentiated carcinomas. In supporting this possibility, a recent study in which more than 100 cell lines and primary tumours were analysed for MAP kinase activity resulted in pancreas and colon tumour cells exhibiting high frequencies of constitutive MAP kinase activation that correlated with a poorly dierentiated tumour phenotype (Hoshino et al., 1999) . On the other hand, another report has shown that sustained activation of the MAP kinase cascade in MDCK cells leads to an epithelial-®broblastic conversion associated with increased migratory and invasive properties (Montesano et al., 1999) .
Materials and methods
Cell culture, treatment conditions and transfection procedures
The origin and characteristics of MCA3D and PDV cell lines have been described previously in several reports (Quintanilla et al., 1991; CaulõÂ n et al., 1995; SantibaÂ nÄ ez et al., 1999) . Cells were grown in Ham's F-12 medium supplemented with amino acids and vitamins (GIBCO, Ltd., Paisley, Scotland), 10% foetal bovine serum, and antibiotics (2.5 mg/ml amphotericin B, 100 mg/ml ampicillin, and 32 mg/ml gentamicin; Sigma Chemical Co., St. Louis, MO, USA). Cultures were maintained on plastic at 378C in a 5% CO 2 humidi®ed atmosphere. MCA3D and PDV cells were co-transfected with an expression vector for the neomycin resistance gene, pcDNA3 (In Vitrogene, San Diego, CA, USA) and plasmids containing a full-length Smad4/DPC4 cDNA or a C-terminal truncated dominant-negative Smad4/DPC4 (1 ± 514) construct (Lagna et al., 1996) , under the control of the cytomegalovirus promoter. The Smad4 plasmids were kindly provided by Dr Joan MassagueÂ (Memorial Sloan-Kettering Cancer Center, New York). Transfections were made in DMEM medium using lipofectamine reagent (Life Technologies, Gaithersburg, MD, USA). Cells were selected in complete Ham's F-12 medium containing 400 mg/ml of G418 (Calbiochem-Novabiochem Co) for 2 weeks, and G418-resistant clones isolated by cloning rings.
Transient co-transfection assays with the 3TP-lux reporter construct and with a lacZ plasmid to score transfection eciency, were performed as described previously (SantibaÂ -nÄ ez et al., 1999) .
For TGF-b 1 treatments, human recombinant TGF-b 1 (Calbiochem-Novabiochem Intl., La Jolla, CA, USA) was used. The growth factor was added to the cell cultures at a ®nal concentration of 10 ng/ml.
For cell growth assays, cells were synchronized by leaving them at con¯uence for 24 h. Equivalent numbers of synchronously growing cells were seeded in 20-cm 2 plates in standard medium. After 18 h, fresh medium with or without TGF-b 1 was added, and the total number of cells determined 48 h later in a Coulter counter.
PD098059 was obtained from Calbiochem-Navabiochem Intl. and added to the cell cultures 20 min prior to stimulation with TGF-b 1 , at the indicated concentrations, in serum-free medium. Then, cells were washed and grown in fresh medium, plus or minus serum, in the presence or absence of TGF-b 1 .
Infection of MCA3D transfectant clones with the Harvey murine sarcoma virus (carrying the viral H-Ras oncogene) was achieved with high-titer viral supernatants obtained by growing C2-MDRas cells to con¯uence, as described by Missero et al. (1991) .
Wound healing assay
Cellular motility was assayed by an in vitro wound model. Subcon¯uent cell monolayers were gently scratched with a tip to produce a`wound'. Then, cultures were allowed to grow for 24 h in standard medium with or without TGF-b 1 . Synthesis of peptide P41 ± 54 (VSYKYFSRIRRCSC), com- Figure 9 Histological appearance of tumours induced by PDV cell transfectants. PC clones gave rise to well dierentiated squamous cell carcinomas as that showed for PC2. PdnS clones produced poorly dierentiated tumours as the one showed for PdnS8, in which squamous dierentiated components were absent or present only in minority regions. Bar, 30 mm prising amino acid residues 41 ± 54 of the EGF-like domain of mouse uPA, and unrelated peptides derived from gelatin by limited trypsin degradation, used as a control, are described elsewhere (SantibaÂ nÄ ez et al., 1999) . Peptides were added to the culture media, at 150 mg/ml, at the same time as TGF-b 1 .
Immunofluorescence analysis
Immuno¯uorescence stainings for Smad2,3 and Erk1,2 proteins were performed by conventional procedures, in cells ®xed and permeabilized in cold methanol, with polyclonal antibodies (Santa Cruz Biotechnology Inc., Santa Cruz, CA, USA): E-20, speci®c for Smad2 and Smad3, and K-23, which recognizes both Erk1 and Erk2 isoforms. Antibodies were used at 1 : 50 dilution in PBS containing 2% BSA. Rhodamine-conjugated anti-goat and anti-rabbit IgG (Jackson ImmunoResearch Lab., West Grove, PA, USA), respectively, were used as secondary antibodies. Dierent ®elds containing 30 ± 60 cells were photographed, and the percentage of cells with Smad2,3 or Erk1,2 accumulated in the nucleus determined counting 10 distinct ®elds from triplicates corresponding to each experimental situation.
Western blot analysis
Cells were lysed in RIPA buer (50 mM NaCl, 1% NP-40, 0,5% sodium deoxycholate, 0,1% SDS, 50 mM Tris-HCl, pH 7.5) and a cocktail of proteinase inhibitors (2 mg/ml aprotinin, 2 mg/ml leupeptin and 1 mM phenylmethylsulphonyl¯uoride). For phospho-Erk determinations, phosphatase inhibitors: 1 mM sodium orthovanadate, 50 mM sodium uoride, 10 mM sodium pyrophosphate and 2 mM hydrogen peroxide, were added to the lysis buer. For Ras protein determinations a lysis buer containing 100 mM NaCl, 5 mM CaCl 2 , 5 mM MgCl 2 , 2% SDS, 50 mM Tris HCl, pH 7.4, and proteinase inhibitors was used. Proteins (20 or 30 mg/lane) were resolved by SDS ± PAGE and transferred to Immobilon P membranes (Millipore Corp., Bedford, MA, USA). Ras proteins were detected by a pan-Ras monoclonal antibody (Ab-3, Oncogene Science Inc., Uniondale, NY, USA). For p21
Cip1 and phospho-Erk1,2 protein determinations, a polyclonal antibody (C-20) and a monoclonal antibody (E-4), respectively, both from Santa Cruz Biothechnology Inc., were used as primary antibodies, followed by exposure to peroxidase-conjugated secondary antibodies (Amersham Intl. Plc. Amersham Bucks, UK), and developed using the enhanced chemoluminescent system (ECL, Amersham Corp., Arlington Heights, FL, USA). The bands detected in the Western blots were quanti®ed by scanning and digitalization of the X-ray ®lms.
Measurement of Ras activation and zymographic assays
The capacity of Ras-GTP to bind the Ras-binding domain of Raf-1 (RBD) was used to analyse the level of active Ras in the cells (de Rooij and Bos, 1997) . Brie¯y, cleared cell lysates (0.7 ± 1.1 mg of total protein) were incubated with 30 mg of the fusion protein GST-RBD bound to glutathione-Sepharose beads. Beads were washed and bound proteins solubilized in Laemmli buer and resolved in SDS ± PAGE. Proteins were then immunoblotted as described above, and precipitated Ras-GTP detected using a pan-Ras monoclonal antibody. The level of Ras protein expression was determined in the cell lysates by Western immunoblotting using the same antibody.
uPA-secreted activity of cell cultures was determined by caseinolytic zymography, as previously reported (SantibaÂ nÄ ez et al., 1999) . Aliquots (20 ± 30 ml) of conditioned serum-free medium, normalized for the same amount of protein (0.5 mg/ ml in PDV experiments, and 2.5 mg/ml in MCA3D experiments), were ®rst subjected to SDS ± PAGE under nonreducing conditions, and then to zymography on agarose gels containing casein and plasminogen.
Tumorigenicity assays and histopathology
Suspensions of 1 ± 2610 6 cells were injected intradermaly into the¯anks of 8 ± 10-week-old Swiss athymic nude mice (CRIFFA, Barcelona, Spain). Animals were observed for tumour formation, and the size of tumours (in cm 2 ) calculated from caliper measurements of two orthogonal diameters at dierent times. Histological typing of all developed tumours was performed on formalin-®xed and paran-embedded sections by staining with hematoxylin and eosin.
